Cathepsin E splice variant 2 appears in a number of gastric carcinomas. Here we report detecting this variant in HeLa cells using polyclonal antibodies and biotinylated inhibitor pepstatin A. An overexpression of GFP fusion proteins of cathepsin E and its splice variant within HEK-293T cells was performed to show their localization. Their distribution under a fl uorescence microscope showed that they are colocalized. We also expressed variants 1 and 2 of cathepsins E, with propeptide and without it, in Escherichia coli . After refolding from the inclusion bodies, the enzymatic activity and circular dichroism spectra of the splice variant 2 were compared to those of the wild-type mature active cathepsins E. While full-length cathepsin E variant 1 is activated at acid pH, the splice variant remains inactive. In contrast to the active cathepsin E, the splice variant 2 predominantly assumes β -sheet structure, prone to oligomerization, at least under in vitro conditions, as shown by atomic force microscopy as shallow disk-like particles. A comparative structure model of splice variant 2 was computed based on its alignment to the known structure of cathepsin E intermediate (Protein Data Bank code 1TZS) and used to rationalize its conformational properties and loss of activity.
Introduction
Aspartic peptidases represent one of the fi ve mechanistic classes of peptidases. Among them, clan AA contains the large A1 family (the pepsin family). The members of this family include cathepsin D and cathepsin E (Rawlings et al. , 2008 ) . In contrast to cathepsin D, which is a widely distributed lysosomal enzyme, cathepsin E, unlike cathepsin D, is not a lysosomal enzyme but has limited cell and tissue distribution (Saku et al. , 1991 ; Bennett et al. , 1992 ) . Cathepsin E was discovered in bone marrow and in rat spleen (Puizdar et al. , 1985 ) . It was found to be present in large amounts in polymorph nuclear cells and in smaller amounts in macrophages (Stefanovic et al. , 1962 ) , in the cells of immune system, including antigen-presenting cells (Yamamoto et al. , 1978 ) , lymphoid tissues, erythrocytes (Yonezawa and Nakamura , 1991 ) , and gastric cells (Samloff et al. , 1987 ) . Cathepsin E is localized in the endosome, plasma membrane, Golgi complex, and endoplasmatic reticulum (Finley and Kornfeld , 1994 ) . For a detailed review, see .
The sequence of cathepsin E resembles the aspartic proteases in the A1 family. The sequence of preprocathepsin E was determined from its isolated cDNA (Azuma et al. , 1992 ) . The known 3D structure of cathepsin E provides some information about activation of an intermediate (Ostermann et al. , 2004 ) . Cathepsin E is expressed in the form of an inactive proenzyme; however, its propeptide is not required for protein stability (Tsukuba et al. , 2006 ) . Complete activation of procathepsin E occurs by proteolytic removal of the N-terminal 36-amino acid residue propeptide (Yasuda et al. , 2005b ) . The maturation generates an exposed active site cleft, with an Asp-Thr-Gly motif from each of the N-and C-terminal protein lobes (Ostermann et al. , 2004 ) . The Asp side chains cleave the peptide bond of a substrate, with the aid of an activated water molecule (James , 2004 ) . Physiological substrates and endogenous protein inhibitors of cathepsin E are not known. The activities of cathepsins E and D are similar and diffi cult to distinguish from each other. However, besides specifi c substrates (Yasuda et al. , 2005a ; Abd -Elgaliel and Tung, 2010 ) , a new approach, based on a combination of a cathepsin E antibody with its substrate, can differentiate their activities in antigen-processing organelles (Zaidi et al. , 2007 ) .
Cathepsin E has been implicated in various physiological and pathological processes. The enzyme participates in processing of the neurotensin precursors and other bioactive peptides (Lees et al. , 1990 ; Kageyama et al. , 1995 ) , as well as functions in antigen processing in dendritic cells (Chain et al. , 2005 ) . Inhibition and gene deletion have been reported to compromise processing and presentation of antigens, such as tetanus toxin, myoglobin, and ovalbumin (Kakehashi et al. , 2007 ; Burster et al. , 2008 ) . Cathepsin E-defi cient mice are also found to spontaneously develop atopic a These authors contributed equally to this work. dermatitis-like skin lesions (Tsukuba et al. , 2003 ) . The enzyme has a substantial role in host defense against tumor cells through TRAIL-dependent apoptosis without affecting normal cells . In particular, it was shown that tumor growth arrest through inhibition of angiogenesis is induced by stable expression of cathepsin E . Recent reviews summarize physiological and pathological processes involving cathepsin E Yamamoto et al. , 2012 ) .
Alternative pre-mRNA processing is a key regulator of gene expression, as it generates numerous transcripts from a single protein-coding gene (Ben -Dov et al., 2008 ) . Alternative splicing generates protein isoforms with different biological properties, differing in protein-protein interactions, subcellular localization, and enzymatic activity (Stamm et al. , 2005 ) . It has been recently shown in two gastric adenocarcinoma cell lines that human procathepsin E gene is subject to alternative splicing (Tatnell et al. , 2003 ) . Interestingly, alternatively spliced transcripts have already been observed for various proteases and appear to be preferentially expressed in cancerous cells and tissues. The procathepsin E gene consists of nine exons (Arnold et al. , 1997 ) , but its splice variant has a deletion of exon 7, consisting of 142 bp (Tatnell et al. , 2003 ) . This deletion dictates a frameshift as exons 8 and 9 are introduced to an alternative transcript. The missing exon 7 encodes the second Asp-Thr-Gly active site motif, presumably resulting in an inactive protein (Tatnell et al. , 2003 ) . Another variant of cathepsin E (variant 3), with an additional 15 bp in its gene, was found in human intestine. The short insert occurs in the intron between exons 4 and 5. No differences in the localization and retention between this variant and cathepsin E were observed (Finley and Kornfeld , 1994 ) .
Here the pro-and mature forms of the splice variant 2 of human cathepsin E have been expressed in Escherichia coli , refolded, and used for biochemical characterization. Cathepsin E activity was confi rmed, whereas its splice form was found to be inactive. A circular dichroism (CD) spectrum of the splice variant allowed us to characterize its oligomeric structure in relation to that of the wild-type cathepsin E. Finally, a comparative structure model of splice variant 2 was computed based on its alignment to the known structure of cathepsin E intermediate (Protein Data Bank (PDB) code 1TZS) and used to rationalize its conformational properties and loss of activity.
Results and discussion
Since the fi rst report of the splice variant of cathepsin E in human intestinal carcinoma cells (Finley and Kornfeld , 1994 ) , an RNA message for this enzyme was also found in gastric adenocarcinoma cells (Tatnell et al. , 2003 ) . No cathepsin E splice variant protein has been reported so far. When we scrutinized HeLa cells for the presence of mRNA of cathepsin E variant 2 and its endogenous expression, low amounts of the mRNA and the protein were indeed detected (Figure 1 ). Polyclonal antibodies used to detect the protein were raised against the peptide from the C-terminal lobe of cathepsin E variant 2, whose sequence bears no apparent relationship to that of normal cathepsin E. The N-terminal part of the molecule of human origin is unchanged and includes a single N-glycosylation, in comparison to rat cathepsin E with two sites (Yasuda et al. , 1999 ; Tsukuba et al. , 2006 ) . Enzymatic deglycosylation, using PNGase F, shows partial N-glycosylation, probably due to a long retention of the protein in endoplasmic reticulum (Figure 1 ). When proteins misfold, they aggregate, thus preventing N-glycosylation. Consequently, they are retained in the ER and later degraded by the proteasome (Ellgaard et al. , 1999 ) . To study localization of both cathepsin E forms in the cell, fusions of cathepsin E with red fl uorescent protein and cathepsin E variant 2 with green fl uorescent protein were coexpressed in HEK-293T cells. The distribution of fusion proteins within cells under a fl uorescence microscope showed that they are colocalized (Figure 2 ) .
Various heterologous gene expression systems have been used to express recombinant cathepsin E and its splice variant for biochemical characterization (Hill et al. , 1993 ; Tsukuba et al. , 1993 ; Yamada et al. , 1994 ) . Acidifi cation rapidly activated the recombinant procathepsin E prepared in E. coli , resulting in a heterogeneous N-terminus of the mature cathepsin E (Hill et al. , 1993 ; Fowler et al. , 1995 ; Tatnell et al. , 1997 ; Ostermann et al. , 2004 ) . To avoid N-terminal microheterogeneity of the resultant mature enzymes, cathepsin E and cathepsin E variant 2 were also expressed without the propeptide. The expression of a cathepsin E mutant with propeptide deletion in mammalian cells yielded a stable protein that was retained in the endoplasmic reticulum, indicating the importance of the propeptide in folding and localization (Yasuda et al. , 2005b ; Tsukuba et al. , 2006 ) . When recombinant mature enzymes were expressed in E. coli , they were in the form of insoluble inclusion bodies. An additional refolding step was required to obtain soluble proteins ( Figure 3 ). Detailed search for a soluble form of the cathepsin E variant 2, using specifi c polyclonal antibodies, showed a low level of protein solubility (Figure 3 ). The ability of the purifi ed recombinant mature cathepsin E to hydrolyze protein substrates with broad specifi city, such as hemoglobin, albumin, and insulin, was compared with that of human cathepsin E variant 2. We found that cathepsin E hydrolyzes the substrates; in contrast, no activity was detected for cathepsin E variant 2. Altering the reaction conditions to neutral pH did not improve the ability of the splice variant 2 to hydrolyze these substrates; however, variant 2 was able to bind pepstatin A. Biotinylated inhibitor (Figure 1 ) or pepstatin A bound to the Sepharose resin (results not shown) and interacted with both variants of cathepsin E from HeLa cell lysate, indicating that the biological function of cathepsin E variant 2 is not completely lost.
Based on the CD spectra, we observed that the mature cathepsin E has assumed a defi ned tertiary structure and a secondary structure typical of an α / β protein ( Figure 4 ). In contrast, the protein containing the propeptide did not refold properly. For cathepsin D, both the proenzyme and the twochain processed enzyme were properly folded in vitro (Lah et al. , 1984 ) . Interestingly, the propeptides of the papain-like cathepsins, such as cathepsins S and L, were involved in the refolding of the mature enzymes (Wiederanders , 2000 ) . For procathepsin L, the propeptide is in a molten globule state at lower pH values, which could play a role in proenzyme Figure 4 CD spectra of cathepsin E (without proregion) and cathepsin E splice variant. The splice variant with proregion and its P286D mutant were also prepared. Near UV CD (informative about tertiary structure) and far UV CD (informative about secondary structure composition) spectra were recorded.
activation (Jerala et al. , 1998 ) . In contrast to the wild-type cathepsin E, the spliced variant 2 apparently folds to a defi ned native state, if it is intact and includes the propeptide. However, it does not possess as intense a CD signal in the near UV range as that of cathepsin E, and its secondary structure composition is predominantly β -sheet, which often leads to the amyloid-like aggregation. Indeed, in the gel fi ltration of the splice variant 2 (Figure 5 A), a peak of high molecular weight has been observed. The protein peak has been isolated and checked for amyloid-like characteristics. The atomic force microscope image ( Figure 5B ) showed shallow disklike particles of height 3-4 nm and diameter of 10-20 nm. The benzothiol dye, Thiofl avin-T (ThT), was used to determine protein self-assembly to amyloid-like aggregate. ThT binding was positive. Additionally, partial N-linked glycosylation could be due to poor folding and therefore retention in the endoplasmic reticulum.
To rationalize the observed conformational properties and lack of activity of cathepsin E splice variant 2, we built its comparative structure model. Several crystal structures are available for A1 aspartic proteases, including the structure of an activation intermediate of cathepsin E (PDB code 1TZS). In the following discussion, we assume that the structure of 1TZS is similar to the structure of cathepsin E variant 1, as the sequences are identical, except for the propeptide in 1TZS. The cathepsin E variant 1 model shows three topologically distinct regions, including an N-terminal domain (residues 67 -200), a C-terminal domain (residues 251 -377), and a six-stranded antiparallel β -sheet between the two terminal domains, comprising three strands that are connecting the N-and C-terminal domains, the propeptide, and the C-terminal β -strand following the C-terminal domain (Ostermann et al. , 2004 ) . Both the N-and C-terminal domains each contribute an Asp-Thr-Gly active site motif with the catalytic aspartic acid residues. Modeling of cathepsin E variant 2, using the structure 1TZS as a template, resulted in a model covering residues 67 -363, with reasonable overall quality criteria values ( Figure 6 ). However, considering the statistically insignifi cant sequence similarity between residues 268 -363 of cathepsin E variant 2 and 1TZS as well as inconclusive fold assignments by the programs MODELLER, GeneThreader (Lobley et al. , 2009 ) and i-Tasser (Roy et al. , 2010 ) , this part of the model should be considered unreliable. To support or reject the cathepsin E variant 2 model, we prepared mutation P268D of cathepsin E variant 2. No activity was observed. Far UV CD spectra of the variant 2 and its P268D mutant show the peak of negative ellipticity at 216 nm, which is characteristic of β -sheet proteins. When the proregion is removed, the secondary structure composition shifts to that characteristic of a more unfolded state. Therefore, it is reasonable to conclude that the structures of the two isoform sequences are similar to each other and 1TZS from the N-terminus to the frameshift. Beyond the frameshift, the sequences are not related. Nevertheless, fold assignments by MODELLER, GeneThreader, and i-Tasser predict a very similar structure for both variants up to residue 300 (Figure  7 A) . The remainder of the sequence of variant 2 is predicted to be mostly β -sheet, with a short helix at residues 340 -345 in some predictions. These results are consistent with secondary structure predictions by PsiPred (Jones , 1999 ) (Figure 7B ) and with experimental CD spectra. Both catalytic aspartate residues in cathepsin E variant 1 are found within the Asp-Thr-Gly motifs (residues 96 -98 and 281 -283), whereas variant 2 only possesses one of these motifs (residues 96 -98); the second motif position 282 -284 is after the frameshift. The mutations of Pro268 or Glu282 into Asp of the cathepsin E variant 2 have been expressed and refolded, and shown to be inactive. Thus, the structure of the splice variant sequence after the frameshift is likely signifi cantly different from that of the wild type.
It is not clear what role, if any, the enzymatically inactive splice variant plays in cells. Recently, it was demonstrated that cathepsin E specifi cally induces tumor growth arrest and apoptosis in human prostate carcinoma cell lines without affecting normal cells . The same group showed that cathepsin E expression in tumor cells induces tumor growth arrest via inhibition of angiogenesis and enhanced immune response . When tumor cells express the functionally inactive splice variant of cathepsin E, probably it substitutes the authentic cathepsin E. The loss of cathepsin E activity and, consequently, an absence of tumor growth arrest can be expected. Another pathological situation due to absence of cathepsin E activity is expected in keratinocyte terminal differentiation, where the cathepsin E activity is functionally linked to the expression of terminal differentiation markers (Kawakubo et al. , 2011 ) .
In conclusion, this study characterized cathepsin E and its inactive splice variant, providing a basis for further studies of the role of cathepsin E spliced variant in pathological conditions.
Materials and methods
The source cDNA clones for cathepsin E (IRAKp961K0951) and cathepsin E splice variant 2 (IMAGp998E045582) were obtained from the Resource Center of the German Human Genome Project (imaGenes, Germany).
Antibodies
An integrated commercial procedure (GenicBio, Shanghai, China) was used to generate peptides, peptide-carrier conjugates for (A) Part of the molecule, colored gray, is predicted to be identical to cathepsin E. The part of the sequence indicated in the green/blue color is predicted to be different from cathepsin E. The blue region (residues 263 -302) is predicted to have a similar fold as variant 1, (one α -helix and 2 β -strands), while the green region of the model (residues 303 -348) is predicted by PsiPred to be predominantly β . The modeled structure for the green region is predicted unreliable. (B) Superposition of the active site residues of the cathepsin E splice variant 2 model (red) with 1TFZ (blue). The Asp-Thr-Gly motifs in 1TFZ and the equivalent residues in cathepsin E splice variant 2 are shown. Black labels indicate identical residue types in both structures.
immunization and antisera. Rabbit polyclonal antibodies were raised against synthetic peptides with an N-terminal Cys to couple the keyhole limpet hemocyanin (KLH). For antibody production against cathepsin E variants 1 and 2, the peptides C-LITGPSDKIKQLQ and C-TLQLGPSGSWGMS, respectively, were used.
RNA isolation and RT-PCR
Total RNA was isolated from HeLa cells using RNeasy Mini Kit (Qiagen, Germany), according to the manufacturer protocol. Two micrograms of total RNA was reverse-transcribed to cDNA using Omniscript RT Kit (Invitrogen) in a 50-µ l total reaction volume, followed by polymerase chain reaction (PCR). For exponential amplification, PCR was performed for 30 cycles, followed by visualization of the product by Sybr Safe (Invitrogen) staining and 1 % agarose gel electrophoresis. The specifi c primers used for cathepsin E variant were described previously (Tatnell et al. , 2003 ) .
Bacterial expression
The cloning and protein expression were carried out as previously described (Hill et al. , 1993 ) . Human cathepsin E and cathepsin E variant 2 (splice variant of cathepsin E) were subcloned without the N-terminal signal sequence. Two recombinant constructs for cathepsin E and two recombinant constructs for cathepsin E variant 2 were prepared. The longer genes encode the enzymes with the propeptide, while the shorter genes encode mature enzymes without the propeptide. Fragments were amplifi ed from the plasmids by PCR, using Pfu polymerase. The primers used in the reaction are shown in Table 1 . In all cloning procedures, NdeI and XhoI restriction sites were introduced for subcloning the PCR products into pET22 and pET28 vectors (Invitrogen, Germany). The nucleotide sequences of newly prepared constructs were verifi ed by DNA sequence analysis (Macrogen, Korea). Expression studies were carried out in the E. coli strain BL21-CodonPlus (DE3)-RP cells (Stratagene, USA). Cells were grown at 37 ° C in 400 ml of Luria-Bertani medium, containing an appropriate antibiotic. The expression was induced with 1 m IPTG. Cells were grown for an additional 3 h, then harvested by centrifugation, followed by resuspending the pellets in 50 ml of Wash buffer (20 m m Tris-HCl pH 7.5, 150 m m NaCl, 1 % Triton X-100). Cells were lysed, by adding lysozyme, to a fi nal protein concentration of 100 µ g/ml and incubating at 37 ° C for 30 min, followed by sonication on ice. Inclusion bodies were collected by centrifugation at 10 000 g for 10 min. The pellet was washed three times with 50 ml of Wash buffer and again collected by centrifugation. The purifi ed inclusion bodies were dissolved in 40 ml of 8 m urea, 20 m m TrisHCl pH 7.5, 150 m m NaCl at room temperature, and centrifuged at 30 000 g for 30 min to remove insoluble material. The solubilized sample was reduced before renaturation with DTT at a fi nal concentration of 150 m m . Renaturation was performed in refolding buffer pH 9.5 (50 m m Tris-HCl pH 9.5, 1 m m EDTA, and 150 m m NaCl). Five milliliters of the cathepsin E variant 2 with a concentration of 15 mg/ml was diluted in 500 ml of refolding buffer pH 9.5. One millimolar reduced glutathione and 0.2 m m oxidized glutathione were added, and then, the solution was dialyzed overnight against 20 m m Tris-HCl pH 8.0, containing 1 m m EDTA. Finally, the protein sample was concentrated. The renaturation of the cathepsin E variant 2 was performed with a similar protocol. The dilution and dialysis were performed with refolding buffer pH 8.0 (50 m m Tris-HCl pH 8.0, 1 m m EDTA, and 150 m m NaCl), and no glutathione was required. Mutations of cathepsin E variant 2 were performed at positions P268D and E282D. The sets of primers each harbored a single amino acid residue mutation (Table 1 ). The amplifi cation of the expression vector pET22 including the cathepsin E variant 2 gene was performed. The PCR products were treated with DpnI to digest the parental DNA template. The reaction mixture was directly transformed into E. coli for amplifi cation. Sequencing verifi ed the mutation. Expression and renaturation were performed for the wild-type protein.
Expression in mammalian cells
Human cathepsin E and cathepsin E variant 2 were subcloned into pDsRed-Monomer-N1 and pEGFP-N2, respectively (Table 1) . Oligonucleotides were designed to allow using the XhoI and KpnI restriction enzymes for subcloning. Preceding the signal sequences of both genes, the Kozak sequence was included. The stop codons were removed to obtain fusions with red and green fl uorescent proteins.
The HEK-293T cells (ATCC, USA) were grown in DMEM medium (Invitrogen, Germany) with Glutamax, supplemented with 10 % solution of FCS, 500 U/ml penicillin, and 500 mg/ml streptomycin to approximately 95 % confl uence in a 10-cm dish. The culture was washed twice in PBS, detached with trypsin, and seeded onto 12-well plates with round 15-mm glass coverslips (Electron Microscopy Sciences, USA) at a density of 100 000 cells/well, 24 h before transfection. On the day of co-transfection, 2 mg of each plasmids DNA were combined, diluted into 500 µ l Optimem medium (Invitrogen, Germany), and supplemented with 2.5 µ l FuGene HD transfection reagent (Roche, Germany). The following procedure was performed according to manufacturer recommendation. Cells were further grown in 12-well dishes on glass coverslips. On the fi rst, second, and third days after transfection, cells on glass coverslips were fi xed in 4 % paraformaldehyde in phosphate-buffered saline and permeabilized with 0.1 % Triton-X100, and then washed four times with 0.1 % glycin in 1 × PBS buffer. Afterwards, fi xed cells were mounted in the The 3 ′ primers used for mammalian cells for catE (cathepsin E) and catEsv (cathepsin E splice variant 2) have been designed for vectors pDsRed-N1 and pEGFP-N2, respectively. d Mutations of mature cathepsin E variant 2 (mat-catE).
Vectashield mounting medium, which includes the DAPI fl uorescent nuclear stain (Vector Labs, Burlingame, CA). The fl uorescence of cell samples was followed with a Hamamatsu Orca-R2 CCD on an inverted Olympus IX-81 microscope. The resulting digitized images were artifi cially colored.
Western blot analysis
Proteins were transferred from SDS electrophoresis onto the PVDF membrane, and detected by goat polyclonal anticathepsin E antibodies (Abcam, UK). Nonspecifi c binding was blocked with 2 % BSA and 0.4 % Tween 20 in PBS, pH 7.4. The membrane was incubated with antibodies to cathepsin E (5 µ g/ml), followed by HRP-conjugated rabbit anti-goat IgG secondary antibody (Jackson ImmunoResearch Lab., USA).
Interaction with the biotinylated pepstatin A and pepstatin A-Sepharose
Pepstatin was labeled with biotin using amine-reactive biotinylation reagent NHS-PEG4-Biotin (Thermo Fisher Scientifi c, Germany) according to manufacturer ' s instructions. Twenty millimolar pepstatin in 50 % methanol was mixed with 2 mg of activated biotin. The cell lysate of three 25-cm 2 tissue culture fl asks (TPP, Switzerland) of confl uent HeLa cells were prepared using nondenaturing extraction buffer (20 m m Tris-HCl, 137 m m NaCl, 10 % glycerol, 1 % Nonidet P-40, 2 m m EDTA pH 8). The extract was incubated with biotinylated pepstatin A for 2 h at 4 ° C, and then, Streptavidin Agarose from the same producer was used to remove unbound proteins. The experiment was performed using pepstatin A-Sepharose affi nity chromatography, as well, under identical conditions as described for purifi cation of cathepsin D (Smith and Turk , 1974 ) . SDS-PAGE and Western blot were performed to analyze binding of cathepsin E and its splice variant.
Immunoprecipitation
The cell lysate of three 25-cm 2 tissue culture fl asks (TPP, Switzerland) of confl uent HeLa cells was prepared using nondenaturing extraction buffer (20 m m Tris-HCl, 137 m m NaCl, 10 % glycerol, 1 % Nonidet P-40, 2 m m EDTA pH 8). Half of the sample was mixed with the specifi c rabbit antibodies against cathepsin E variant 1 and another half with the specifi c rabbit antibodies against cathepsin E variant 2. Samples were incubated overnight at 4 ° C and applied on protein A Sepharose (GE Healthcare). Nonspecifi cally bound proteins were removed at pH 8.5 (150 m m glycine/NaOH buffer), and proteins were eluted at pH 3.5 (20 m m glycine/HCl buffer). The eluted sample was immediately neutralized to pH 8.0 using 1 m Tris-HCl buffer. Both samples were analyzed with SDS-PAGE and Western blot using polyclonal mouse antibodies against cathepsin E.
Enzyme assay
Cathepsin E activity was assayed according to the protocols published for the KYS-1 substrate (MOCAc-Gly-Ser-Pro-Ala-Phe-Leu-AlaLys(Dnp)-D-Arg-NH 2 ) (Yasuda et al. , 2005a ) , FITC-hemoglobin, albumin, insulin, and substance P, as well as in 100 m m sodium phosphate buffer pH 7.0.
Deglycosylation of cathepsin E variant 2
The cell lysate of HeLa cells was prepared under denaturation conditions using RIPA buffer. Five hundred micrograms of sample was deglycosylated using PNGase F (New England Biolabs, UK) or Endo H (New England Biolabs, UK) under reducing conditions according to the manufacturer ' s instructions. All reactions were performed in duplicate. Deglycosylated lysates and media were characterized by SDS-PAGE analysis and Western blotting.
CD spectra measurements
CD spectra were recorded using an Aviv (Lakewood, NJ, USA) model 60 DS CD spectropolarimeter. Ten-millimeter minirectangular cell (near UV CD), 1-mm rectangular cell, and 0.2 mm demountable rectangular cell (both for far UV CD) were used. The corresponding bandwidths were set at 0.5 nm (for the near UV) and 1.0 nm (for the far UV). The temperature was 20 ° C. Data in the far UV were collected every 1 nm, using a scan rate of 0.25 nm/s and data in the near UV every 0.5 nm at a scan rate of 0.16 nm/s. The usual protein concentration was A 280 = 1.8 for the near UV and A 280 = 0.3 for the far UV region. As no extinction coeffi cient are known for cathepsin E and its splice variant, the mean residue weight ellipticity was recalculated to deg cm 2 /dmol using estimated extinction coeffi cients.
Structural analysis
Comparative protein structure modeling was carried out using the automated comparative protein structure modeling pipeline MODPIPE (Pieper et al. , 2011 ) , which relies primarily on various modules of MODELLER (Sali and Blundell , 1993 ) for its functionality. Briefl y, template selection was performed using a variety of sequence-sequence, sequence-profi le, and profi le-profi le methods, using an E-value threshold of 1.0, and the resulting alignments were then used to compute comparative models using MODELLER. The resulting model was assessed to be reliable by the normalized DOPE (-0.37), GA341 (1.0), and MPQS (1.3) scores (Pieper et al., 2011) . More details are available at http://salilab.org/modbase/search ? dataset_name = MW-cath_E.
